Hijack Bio

Executive Summary

Hijack Bio is a UK-based biotechnology company founded in 2021, developing environmentally aware targeted biogenic drug delivery systems. The company's platform aims to improve precision and reduce off-target effects for biotherapeutics by utilizing novel biogenic carriers that are both targeted and environmentally conscious. This approach addresses key challenges in drug delivery, particularly for biologics, where targeted delivery remains a significant hurdle. Hijack Bio's technology has potential applications across various therapeutic areas, including oncology, inflammation, and rare diseases. The company operates in the rapidly growing drug delivery market, valued at over $50 billion, with increasing demand for precision therapies. While still in early stages, Hijack Bio's focus on biogenic materials aligns with industry trends toward sustainable and biocompatible solutions. However, the company faces significant competition from established players and other startups in the targeted delivery space. Given its early stage and lack of disclosed funding, the company's progress is likely dependent on securing seed or Series A financing. A successful funding round or strategic partnership could validate its platform and accelerate development.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement50% success
• Q3 2026Preclinical Proof-of-Concept Data Release40% success
• Q2 2027Pharmaceutical Partnership or Collaboration20% success